T

Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM

Watchlist Manager
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Watchlist
Price: 3 209.8501 INR -0.49% Market Closed
Market Cap: 1.1T INR
Have any thoughts about
Torrent Pharmaceuticals Ltd?
Write Note

Torrent Pharmaceuticals Ltd
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Torrent Pharmaceuticals Ltd
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cash Equivalents
â‚ą11.5B
CAGR 3-Years
49%
CAGR 5-Years
14%
CAGR 10-Years
7%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cash Equivalents
â‚ą7.1B
CAGR 3-Years
-22%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cash Equivalents
â‚ą9.2B
CAGR 3-Years
-14%
CAGR 5-Years
-4%
CAGR 10-Years
16%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cash Equivalents
â‚ą90.2B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
4%
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Cash Equivalents
â‚ą6.9B
CAGR 3-Years
1%
CAGR 5-Years
10%
CAGR 10-Years
2%
M
Mankind Pharma Ltd
NSE:MANKIND
Cash Equivalents
â‚ą1.2B
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Torrent Pharmaceuticals Ltd
Glance View

Market Cap
1.1T INR
Industry
Pharmaceuticals
Economic Moat
Narrow

Torrent Pharmaceuticals Ltd. has steadily carved a niche for itself as a formidable player in the global pharmaceutical landscape. Founded in 1959 in India, the company specializes in developing, manufacturing, and marketing a diverse portfolio of generic and branded formulations across therapeutic areas such as cardiovascular, central nervous system, and diabetology, among others. With a robust presence in over 40 countries and a strong focus on research and development, Torrent has established partnerships and collaborations that bolster its ability to innovate and expand its product offerings. The company’s commitment to quality and regulatory compliance is evident as it operates multiple state-of-the-art manufacturing facilities certified by global regulatory bodies, ensuring that their products meet the highest international standards. For investors, Torrent Pharmaceuticals presents a compelling opportunity characterized by steady growth and a focus on long-term value creation. In recent years, the company has demonstrated resilience despite market challenges, driven by a growing demand for affordable medicines and its strategic focus on expanding its international footprint, particularly in regulated markets. The firm’s robust pipeline of products, coupled with its strengths in key therapeutic segments, positions it well for future growth. Furthermore, Torrent’s consistent financial performance and prudent management practices reflect the core principles of value investing, making it an attractive consideration for those looking to invest in a company that not only prioritizes profitability but also contributes positively to global healthcare outcomes. As the pharmaceutical industry continues to evolve, Torrent Pharmaceuticals Ltd. stands ready to navigate the complexities ahead while delivering sustained shareholder value.

TORNTPHARM Intrinsic Value
1 953.2021 INR
Overvaluation 39%
Intrinsic Value
Price
T

See Also

What is Torrent Pharmaceuticals Ltd's Cash Equivalents?
Cash Equivalents
11.5B INR

Based on the financial report for Sep 30, 2024, Torrent Pharmaceuticals Ltd's Cash Equivalents amounts to 11.5B INR.

What is Torrent Pharmaceuticals Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
7%

Over the last year, the Cash Equivalents growth was 107%. The average annual Cash Equivalents growth rates for Torrent Pharmaceuticals Ltd have been 49% over the past three years , 14% over the past five years , and 7% over the past ten years .

Back to Top